High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis.
Twenty patients with lung cancer, treated with cisplatin and etoposide, were divided into two groups at random and given antiemetic therapy consisting of either high-dose metoclopramide (MCL) intravenously (8 mg/kg over 7 hours) and chlorpromazine (CPZ) (50 mg orally), or a reduced dose of MCL (6 mg/kg over 7 hours) and CPZ (50 mg orally). Serum MCL concentrations were monitored during the infusions. In the two groups, 33% and 38% vomited during and after the courses, and antiemetic control was achieved in 83% and 75% of the patients. There was no significant difference between the groups, and side effects were negligible. MCL concentrations exceeded 0.7 microgram/ml in all patients, with great inter-individual variation.
Aasebø
U
U
Slørdal
L
L
Prytz
P S
PS
Aarbakke
J
J
D000328:Adult; D000368:Aged; D002746:Chlorpromazine / Q000097:blood / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007700:Kinetics; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008787:Metoclopramide / Q000097:blood / Q000627:therapeutic use*; D008875:Middle Aged; D011897:Random Allocation; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D005047:Etoposide; D008787:Metoclopramide; D002945:Cisplatin; D002746:Chlorpromazine